Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Buder, Kristina ^a   Lapa, Constantin ^a   Kreissl, Michael C ^a,b   Schirbel, Andreas ^a   Herrmann, Ken ^a   Schnack, Alexander ^a   Bröcker, Eva Bettina ^a   Goebeler, Matthias ^a   Buck, Andreas K ^a   Becker, Jürgen C ^a,c  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Merkel cell carcinoma; Molecular imaging; Positron emission tomography; Somatostatin receptor expression

Indexed keywords

1,4,7,10 TETRAAZACYCLO DODECANE N,N',N'',N'' TETRAACETICACID DEXTRO PHENYLALANINE OCTREOTATE[3 TYROSINE] GA 68; 1,4,7,10 TETRAAZACYCLO DODECANE N,N',N'',N'' TETRAACETICACID DEXTRO PHENYLALANINE OCTREOTIDE[3 TYROSINE] GA 68; CISPLATIN; DOXORUBICIN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; EDOTREOTIDE; OCTREOTIDE; SOMATOSTATIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; MOLECULAR IMAGING; PATIENT CARE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE METASTASIS; TUMOR VOLUME; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BRAIN TUMOR; CARCINOMA, MERKEL CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, MERKEL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR IMAGING; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899632739     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-268     Document Type: Article

References (36)

1. Schrama D, Ugurel S, Becker JC. Merkel cell carcinoma: recent insights and new treatment options. Curr Opin Oncol 2012, 24(2):141-149. 10.1097/CCO.0b013e32834fc9fe, 22234254.
2. Agelli M, Clegg LX, Becker JC, Rollison DE. The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer 2010, 34(1):14-37. 10.1016/j.currproblcancer.2010.01.001, 20371072.
3. Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W. Somatostatin analogue scintigraphy in Merkel cell tumours. Br J Dermatol 2003, 148(6):1135-1140. 10.1046/j.1365-2133.2003.05338.x, 12828740.
4. Fantini F, Johansson O. Neurochemical markers in human cutaneous Merkel cells. An immunohistochemical investigation. Exp Dermatol 1995, 4(6):365-371. 10.1111/j.1600-0625.1995.tb00061.x, 8608344.
5. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010, 63(5):751-761. 10.1016/j.jaad.2010.02.056, 2956767, 20646783.
6. Becker JC, Assaf C, Vordermark D, Reske SN, Hense J, Dettenborn T, Seitz O, Grabbe S. German guideline Merkel Cell Carcinoma. JDDG 2013, Suppl. 3:31-38.
7. Boccara O, Girard C, Mortier L, Bens G, Saiag P, Guillot B. Guidelines for the diagnosis and treatment of Merkel cell carcinoma - Cutaneous Oncology Group of the French Society of Dermatology. Eur J Dermatol 2012, 22(3):375-379.
8. Colgan MB, Tarantola TI, Weaver AL, Wiseman GA, Roenigk RK, Brewer JD, Otley CC. The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma. J Am Acad Dermatol 2012, 67(6):1250-1256. 10.1016/j.jaad.2012.03.018, 22552001.
9. Sarnaik AA, Zager JS, Cox LE, Ochoa TM, Messina JL, Sondak VK. Routine omission of sentinel lymph node biopsy for merkel cell carcinoma < = 1 cm is not justified. J Clin Oncol 2010, 28(1):e7. 10.1200/JCO.2009.25.9937, 19933899.
10. Schwartz JL, Griffith KA, Lowe L, Wong SL, McLean SA, Fullen DR, Lao CD, Hayman JA, Bradford CR, Rees RS, Johnson TM, Bichakjian CK. Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol 2011, 29(8):1036-1041. 10.1200/JCO.2010.33.4136, 21300936.
11. Stokes JB, Graw KS, Dengel LT, Swenson BR, Bauer TW, Slingluff CL, Ledesma EJ. Patients with Merkel cell carcinoma tumors < or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis. J Clin Oncol 2009, 27(23):3772-3777. 10.1200/JCO.2008.20.8272, 2727285, 19581538.
12. Belhocine T, Pierard GE, Fruhling J, Letesson G, Bolle S, Hustinx R, Dargent JL, Flamen P, Rigo P. Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. Oncol Rep 2006, 16(2):347-352.
13. Concannon R, Larcos GS, Veness M. The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia. J Am Acad Dermatol 2010, 62(1):76-84. 10.1016/j.jaad.2009.06.021, 20082888.
14. Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and women's cancer center. J Am Acad Dermatol 2013, 68(4):592-599. 10.1016/j.jaad.2012.08.042, 23127473.
15. Maury G, Dereure O, Du-Thanh A, Mariano-Goulart D, Guillot B. Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients. J Eur Acad Dermatol Venereol 2011, 25(12):1420-1427. 10.1111/j.1468-3083.2011.03994.x, 21366705.
16. Peloschek P, Novotny C, Mueller-Mang C, Weber M, Sailer J, Dawid M, Czerny C, Dudczak R, Kletter K, Becherer A. Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol 2010, 73(2):317-323. 10.1016/j.ejrad.2008.10.032, 19108971.
17. Siva S, Byrne K, Seel M, Bressel M, Jacobs D, Callahan J, Laing J, Macmanus MP, Hicks RJ. 18 F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med 2013, 54(8):1223-1229. 10.2967/jnumed.112.116814, 23753187.
18. Kwekkeboom DJ, Hoff AM, Lamberts SW, Oei HY, Krenning EP. Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol 1992, 128(6):818-821. 10.1001/archderm.1992.01680160102014, 1599271.
19. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001, 28(12):1751-1757. 10.1007/s002590100639, 11734911.
20. Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011, 38(7):1224-1236. 10.1007/s00259-011-1760-x, 21369945.
21. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009, 36(1):48-52. 10.1007/s00259-008-0944-5, 18807033.
22. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, von Guggenberg E, Bale R, Virgolini IJ. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48(4):508-518. 10.2967/jnumed.106.035667, 17401086.
23. Schneider C, Schlaak M, Bludau M, Markiefka B, Schmidt MC. 68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma. Clin Nucl Med 2012, 37(11):1108-1111. 10.1097/RLU.0b013e318266d3b3, 22996252.
24. Epstude M, Tornquist K, Riklin C, di Lenardo F, Winterhalder R, Hug U, Strobel K. Comparison of 18 F-FDG PET/CT and 68Ga-DOTATATE PET/CT imaging in Metastasized Merkel cell carcinoma. Clin Nucl Med 2013, 38(4):283-284. 10.1097/RLU.0b013e318281658e, 23429397.
25. Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011, 41(4):314-321. 10.1053/j.semnuclmed.2011.02.001, 21624565.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
27. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P, Canc EORT. Measurement of clinical and subclinical tumour response using [F-18]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999, 35(13):1773-1782. 10.1016/S0959-8049(99)00229-4, 10673991.
28. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009, 50(8):1214-1221. 10.2967/jnumed.108.060236, 19617343.
29. Bailey TL, Fung MA, Gandour-Edwards R, Ellis WG, Schrot RJ. Clinical emergence of neurometastatic merkel cell carcinoma: a surgical case series and literature review. J Neurooncol 2011, 102(1):147-155. 10.1007/s11060-010-0304-8, 3041920, 20668913.
30. Guitera-Rovel P, Lumbroso J, Gautier-Gougis MS, Spatz A, Mercier S, Margulis A, Mamelle G, Kolb F, Lartigau E, Avril MF. Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol 2001, 12(6):807-811. 10.1023/A:1011142410535, 11484956.
31. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 1999, 85(12):2589-2595. 10.1002/(SICI)1097-0142(19990615)85:12<2589::AID-CNCR15>3.0.CO;2-F, 10375107.
32. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian trials in medical oncology group. Cancer 1996, 77(2):402-408. 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4, 8625251.
33. Fakiha M, Letertre P, Vuillez JP, Lebeau J. Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther 2010, 6(3):382-384. 10.4103/0973-1482.73352, 21119285.
34. Meier G, Waldherr C, Herrmann R, Maecke H, Mueller-Brand J, Pless M. Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. a case report. Oncology 2004, 66(2):160-163. 10.1159/000077443, 15138369.
35. Salavati A, Prasad V, Schneider CP, Herbst R, Baum RP. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med 2012, 26(4):365-369. 10.1007/s12149-012-0578-3, 22361935.
36. Schmidt MC, Uhrhan K, Markiefka B, Hasselbring L, Schlaak M, Cremer B, Kunze S, Baum RP, Dietlein M. (68)Ga-DotaTATE PET-CT followed by peptide receptor radiotherapy in combination with capecitabine in two patients with merkel cell carcinoma. Int J Clin Exp Med 2012, 5(4):363-366. 3526339, 23293710.